Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00189137 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT00189137 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 84 participants.
The verdict
NCT00189137, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to explore how a sarcoma is affected by and the side effects of a newer combination of chemotherapy drugs(gemcitabine and docetaxel)as compared to a standard combination of chemotherapy drugs, ifosfamide and doxorubicin.
Interventions
- DRUG ifosfamide and doxorubicin vs gemcitabine and docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2004-08 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00189137
The ClinicalTrials.gov registry entry for NCT00189137 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ifosfamide and doxorubicin vs gemcitabine and docetaxel is the first listed.
NCT00189137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00189137 about?
NCT00189137 is a clinical study titled "Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma". The purpose of this study is to explore how a sarcoma is affected by and the side effects of a newer combination of chemotherapy drugs(gemcitabine and docetaxel)as compared to a standard combination of chemotherapy drugs, ifosfamide and doxorubicin.
What is the current status of trial NCT00189137?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2004-08. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00189137?
The interventions under investigation include: ifosfamide and doxorubicin vs gemcitabine and docetaxel (DRUG).
Who is sponsoring clinical trial NCT00189137?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.